This report provides a comprehensive analysis of the global CD19-targeted CAR-T cell therapy market, which is projected to experience significant growth through 2032. It examines key market dynamics, including therapeutic applications for lymphoma and lymphocytic leukemia, while evaluating major players like Gilead, Novartis, and Bristol-Myers Squibb. The study offers detailed regional insights across the Americas, APAC, and Europe, highlighting emerging opportunities, competitive strategies, and technological trends shaping this evolving immunotherapy landscape.

Market Overview

Global Market Projections

The global CD19-targeted CAR-T Cell Therapy market size is predicted to grow from US$ 3508 million in 2025 to US$ 9852 million in 2032, representing a compound annual growth rate (CAGR) of 16.2% from 2026 to 2032.

Technology Definition and Context

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.

Currently available CAR-T cell therapy products are divided into:

• CD19 targets: The most common target; CD19 is a protein found on the surface of most B-cells, including malignant B-cells in certain types of leukemia and lymphoma.
• BCMA targets

Regional Market Analysis

United States

The United States market for CD19-targeted CAR-T Cell Therapy is expected to experience significant growth from 2025 through 2032.

China

The China market for CD19-targeted CAR-T Cell Therapy is projected to expand steadily between 2025 and 2032.

Europe

The Europe market for CD19-targeted CAR-T Cell Therapy is anticipated to see an increase in market value from 2025 to 2032.

Market Segmentation

By Type

• Yescarta
• Kymriah
• Tecartus
• Others

By Application

• Lymphoma
• Lymphocytic Leukemia

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Global Players

The following companies have been profiled based on primary expert input and analysis of their company coverage, product portfolio, and market penetration:

• Gilead: (Yescarta & Tecartus)
• Novartis: (Kymriah)
• Bristol-Myers Squibb: (Breyanzi)
• FOSUNKite: (Yescarta)
• Shanghai Yaoming Juno: (Carteyva)
• Juventas

Market Concentration

In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

About the Research Report

Scope and Methodology

LPI (LP Information)' newest research report, the “CD19-targeted CAR-T Cell Therapy Industry Forecast,” looks at past sales and reviews total world CD19-targeted CAR-T Cell Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected CD19-targeted CAR-T Cell Therapy sales for 2026 through 2032.

With CD19-targeted CAR-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD19-targeted CAR-T Cell Therapy industry. The study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a highly nuanced view of the current state and future trajectory in the global CD19-targeted CAR-T Cell Therapy market.

Key Insights Provided

This Insight Report provides a comprehensive analysis of the global CD19-targeted CAR-T Cell Therapy landscape and highlights:

• Key Trends: Product segmentation, company formation, revenue, and market share.
• Market Dynamics: Latest developments and M&A activity.
• Strategic Analysis: Analysis of leading global companies' strategies, focusing on CD19-targeted CAR-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints.
• Opportunity Identification: Evaluation of key market trends, drivers, and affecting factors to highlight emerging pockets of opportunity by Type, Application, geography, and market size.

Summary of Deliverables

The report presents a comprehensive overview, market shares, and growth opportunities of the CD19-targeted CAR-T Cell Therapy market by product type, application, key players, and key regions and countries.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global CD19-targeted CAR-T Cell Therapy Market Size (2021-2032)

    • 2.1.2 CD19-targeted CAR-T Cell Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for CD19-targeted CAR-T Cell Therapy by Country/Region (2021, 2025 & 2032)

  • 2.2 CD19-targeted CAR-T Cell Therapy Segment by Type

    • 2.2.1 Yescarta

    • 2.2.2 Kymriah

    • 2.2.3 Tecartus

    • 2.2.4 Others

    • 2.2.5 CD19-targeted CAR-T Cell Therapy Market Size by Type

      • 2.2.5.1 CD19-targeted CAR-T Cell Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.5.2 Global CD19-targeted CAR-T Cell Therapy Market Size Market Share by Type (2021-2026)

  • 2.3 CD19-targeted CAR-T Cell Therapy Segment by Application

    • 2.3.1 Lymphoma

    • 2.3.2 Lymphocytic Leukemia

    • 2.3.3 CD19-targeted CAR-T Cell Therapy Market Size by Application

      • 2.3.3.1 CD19-targeted CAR-T Cell Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.3.2 Global CD19-targeted CAR-T Cell Therapy Market Size Market Share by Application (2021-2026)

• 3 CD19-targeted CAR-T Cell Therapy Market Size by Player

  • 3.1 CD19-targeted CAR-T Cell Therapy Market Size Market Share by Player

    • 3.1.1 Global CD19-targeted CAR-T Cell Therapy Revenue by Player (2021-2026)

    • 3.1.2 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Player (2021-2026)

  • 3.2 Global CD19-targeted CAR-T Cell Therapy Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 CD19-targeted CAR-T Cell Therapy by Region

  • 4.1 CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2026)

  • 4.2 Global CD19-targeted CAR-T Cell Therapy Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas CD19-targeted CAR-T Cell Therapy Market Size Growth (2021-2026)

  • 4.4 APAC CD19-targeted CAR-T Cell Therapy Market Size Growth (2021-2026)

  • 4.5 Europe CD19-targeted CAR-T Cell Therapy Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)

  • 5.2 Americas CD19-targeted CAR-T Cell Therapy Market Size by Type (2021-2026)

  • 5.3 Americas CD19-targeted CAR-T Cell Therapy Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2026)

  • 6.2 APAC CD19-targeted CAR-T Cell Therapy Market Size by Type (2021-2026)

  • 6.3 APAC CD19-targeted CAR-T Cell Therapy Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)

  • 7.2 Europe CD19-targeted CAR-T Cell Therapy Market Size by Type (2021-2026)

  • 7.3 Europe CD19-targeted CAR-T Cell Therapy Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa CD19-targeted CAR-T Cell Therapy by Region (2021-2026)

  • 8.2 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global CD19-targeted CAR-T Cell Therapy Market Forecast

  • 10.1 Global CD19-targeted CAR-T Cell Therapy Forecast by Region (2027-2032)

    • 10.1.1 Global CD19-targeted CAR-T Cell Therapy Forecast by Region (2027-2032)

    • 10.1.2 Americas CD19-targeted CAR-T Cell Therapy Forecast

    • 10.1.3 APAC CD19-targeted CAR-T Cell Therapy Forecast

    • 10.1.4 Europe CD19-targeted CAR-T Cell Therapy Forecast

    • 10.1.5 Middle East & Africa CD19-targeted CAR-T Cell Therapy Forecast

  • 10.2 Americas CD19-targeted CAR-T Cell Therapy Forecast by Country (2027-2032)

    • 10.2.1 United States Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.2.2 Canada Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.2.3 Mexico Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.2.4 Brazil Market CD19-targeted CAR-T Cell Therapy Forecast

  • 10.3 APAC CD19-targeted CAR-T Cell Therapy Forecast by Region (2027-2032)

    • 10.3.1 China CD19-targeted CAR-T Cell Therapy Market Forecast

    • 10.3.2 Japan Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.3.3 Korea Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.3.4 Southeast Asia Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.3.5 India Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.3.6 Australia Market CD19-targeted CAR-T Cell Therapy Forecast

  • 10.4 Europe CD19-targeted CAR-T Cell Therapy Forecast by Country (2027-2032)

    • 10.4.1 Germany Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.4.2 France Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.4.3 UK Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.4.4 Italy Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.4.5 Russia Market CD19-targeted CAR-T Cell Therapy Forecast

  • 10.5 Middle East & Africa CD19-targeted CAR-T Cell Therapy Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.5.2 South Africa Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.5.3 Israel Market CD19-targeted CAR-T Cell Therapy Forecast

    • 10.5.4 Turkey Market CD19-targeted CAR-T Cell Therapy Forecast

  • 10.6 Global CD19-targeted CAR-T Cell Therapy Forecast by Type (2027-2032)

  • 10.7 Global CD19-targeted CAR-T Cell Therapy Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market CD19-targeted CAR-T Cell Therapy Forecast

• 11 Key Players Analysis

  • 11.1 Gilead (Yescarta&Tecartus)

    • 11.1.1 Gilead (Yescarta&Tecartus) Company Information

    • 11.1.2 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.1.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Gilead (Yescarta&Tecartus) Main Business Overview

    • 11.1.5 Gilead (Yescarta&Tecartus) Latest Developments

  • 11.2 Novartis (Kymriah)

    • 11.2.1 Novartis (Kymriah) Company Information

    • 11.2.2 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.2.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Novartis (Kymriah) Main Business Overview

    • 11.2.5 Novartis (Kymriah) Latest Developments

  • 11.3 Bristol-Myers Squibb (Breyanzi)

    • 11.3.1 Bristol-Myers Squibb (Breyanzi) Company Information

    • 11.3.2 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.3.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Bristol-Myers Squibb (Breyanzi) Main Business Overview

    • 11.3.5 Bristol-Myers Squibb (Breyanzi) Latest Developments

  • 11.4 FOSUNKite (Yescarta)

    • 11.4.1 FOSUNKite (Yescarta) Company Information

    • 11.4.2 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 FOSUNKite (Yescarta) Main Business Overview

    • 11.4.5 FOSUNKite (Yescarta) Latest Developments

  • 11.5 Shanghai Yaoming Juno (Carteyva)

    • 11.5.1 Shanghai Yaoming Juno (Carteyva) Company Information

    • 11.5.2 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.5.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Shanghai Yaoming Juno (Carteyva) Main Business Overview

    • 11.5.5 Shanghai Yaoming Juno (Carteyva) Latest Developments

  • 11.6 Juventas

    • 11.6.1 Juventas Company Information

    • 11.6.2 Juventas CD19-targeted CAR-T Cell Therapy Product Offered

    • 11.6.3 Juventas CD19-targeted CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Juventas Main Business Overview

    • 11.6.5 Juventas Latest Developments

• 12 Research Findings and Conclusion